WebCurrent or prior use of immunosuppressive medication within 2 weeks prior to the first dose of TAB004, with the exception of intranasal and inhaled corticosteroids or systemic … WebFour TAB004 dose levels are planned and include: 0.3, 1, 3 and 10 mg/kg. Part A will be the traditional 3 + 3 design with 3 to 6 subjects per dose level (cohort) and will receive their …
A Study of Atezolizumab Plus Tiragolumab in Combination With …
WebNov 6, 2024 · The aim of this clinical trial was to evaluate the efficacy of Relatlimab as a monotherapy or in combination with Nivolumab (anti-PD-1 antibody) in patients with various advanced malignancies including melanoma, NSCLC, and RCC [ 20 ]. WebIcatolimab (JS004 or TAB004) is a humanized IgG4 monoclonal antibody with a hinge mutation (S228P) that binds BTLA and blocks its interaction with its ligand HVEM. In this first-in-human study, we report the preliminary safety and anti-tumor activity of icatolimab as a single agent or in combination with toripalimab (anti-PD-1) in patients with ... ogham cards
Frontiers Combining the Specific Anti-MUC1 Antibody TAB004 …
WebThe exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and... WebFind technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes links to find associated clinical trials. WebOVERVIEW: This is a Phase 1, multi-center, open-label, dose-escalation study of TAB004, a recombinant humanized IgG4κ monoclonal antibody specific to BTLA when administered … ogham divination set